85 research outputs found
5-Vinylphosphonate improves tissue accumulation and efficacy of conjugated siRNAs in vivo
5-Vinylphosphonate modification of siRNAs protects them from phosphatases, and improves silencing activity. Here, we show that 5-vinylphosphonate confers novel properties to siRNAs. Specifically, 5-vinylphosphonate (i) increases siRNA accumulation in tissues, (ii) extends duration of silencing in multiple organs and (iii) protects siRNAs from 5-to-3 exonucleases. Delivery of conjugated siRNAs requires extensive chemical modifications to achieve stability in vivo. Because chemically modified siRNAs are poor substrates for phosphorylation by kinases, and 5-phosphate is required for loading into RNA-induced silencing complex, the synthetic addition of a 5-phosphate on a fully modified siRNA guide strand is expected to be beneficial. Here, we show that synthetic phosphorylation of fully modified cholesterol-conjugated siRNAs increases their potency and efficacy in vitro, but when delivered systemically to mice, the 5-phosphate is removed within 2 hours. The 5-phosphate mimic 5-(E)-vinylphosphonate stabilizes the 5 end of the guide strand by protecting it from phosphatases and 5-to-3 exonucleases. The improved stability increases guide strand accumulation and retention in tissues, which significantly enhances the efficacy of cholesterol-conjugated siRNAs and the duration of silencing in vivo. Moreover, we show that 5-(E)-vinylphosphonate stabilizes 5 phosphate, thereby enabling systemic delivery to and silencing in kidney and heart
The expression of CXCR4/CXCL12 determines subsets of patients in systemic lupus erythematosus
Hydrophobicity drives the systemic distribution of lipid-conjugated siRNAs via lipid transport pathways
Efficient delivery of therapeutic RNA beyond the liver is the fundamental obstacle preventing its clinical utility. Lipid conjugation increases plasma half-life and enhances tissue accumulation and cellular uptake of small interfering RNAs (siRNAs). However, the mechanism relating lipid hydrophobicity, structure, and siRNA pharmacokinetics is unclear. Here, using a diverse panel of biologically occurring lipids, we show that lipid conjugation directly modulates siRNA hydrophobicity. When administered in vivo, highly hydrophobic lipid-siRNAs preferentially and spontaneously associate with circulating low-density lipoprotein (LDL), while less lipophilic lipid-siRNAs bind to high-density lipoprotein (HDL). Lipid-siRNAs are targeted to lipoprotein receptor-enriched tissues, eliciting significant mRNA silencing in liver (65%), adrenal gland (37%), ovary (35%), and kidney (78%). Interestingly, siRNA internalization may not be completely driven by lipoprotein endocytosis, but the extent of siRNA phosphorothioate modifications may also be a factor. Although biomimetic lipoprotein nanoparticles have been explored for the enhancement of siRNA delivery, our findings suggest that hydrophobic modifications can be leveraged to incorporate therapeutic siRNA into endogenous lipid transport pathways without the requirement for synthetic formulation
Gene therapy with AR isoform 2 rescues spinal and bulbar muscular atrophy phenotype 2 by modulating AR transcriptional activity:AR isoform 2 counteracts polyglutamine AR toxicity
Spinal and bulbar muscular atrophy (SBMA) is an X-linked, adult-onset neuromuscular condition caused by an abnormal polyglutamine (polyQ) tract expansion in androgen receptor (AR) protein. SBMA is a disease with high unmet clinical need. Recent studies have shown that mutant AR-altered transcriptional activity is key to disease pathogenesis. Restoring the transcriptional dysregulation without affecting other AR critical functions holds great promise for the treatment of SBMA and other AR-related conditions; however, how this targeted approach can be achieved and translated into a clinical application remains to be understood. Here, we characterized the role of AR isoform 2, a naturally occurring variant encoding a truncated AR lacking the polyQ-harboring domain, as a regulatory switch of AR genomic functions in androgen-responsive tissues. Delivery of this isoform using a recombinant adeno-associated virus vector type 9 resulted in amelioration of the disease phenotype in SBMA mice by restoring polyQ AR-dysregulated transcriptional activity
Tenothiovir and Adethiovir : new acyclic phosphonate analogs targering HIV-1 resistant strains
Les virus de l'Immunodéficience Humaine de type 1 et 2 (HIV-1 et HIV-2) et de l'Hépatite B (HBV) représentent un intérêt particulier en santé publique. En effet, on estime à plus de 33 millions le nombre de personnes infectées par le virus HIV dans le monde et 360 millions par HBV. La transcriptase inverse (RT) est une enzyme nécessaire à leur réplication et constitue donc une cible majeure des drogues antivirales. Parmi les NRTI commercialisés, les analogues de nucleotides de type phosphonates acyclique, comme l'Adefovir (HEPSERA®, Gilead) et le Tenofovir (VIREAD®, Gilead) sous forme prodrogue, ont révolutionné les traitements contre les virus HBV et HIV. Devant l'emmergence de virus résistants, il est urgent de développer de nouveaux antiviraux plus puissants et surtout actifs sur ces souches afin d'optimiser les multithérapies antivirales. Dans ce but, nous avons conçu des analogues thiophosphonates dérivés de l'Adefovir (PMEA) et du Tenofovir (PMPA), non toxiques pour la cellules et actifs contre HIV-1, HIV-2 et HBV en culture de cellules infectées. Ces composés, baptisés Adethiovir et Tenothiovir, ont été synthétisés selon une méthode originale et ont fait l'objet d'un dépôt de brevet. Nous avons synthétisé les formes diphosphates correspondantes : incorporés par la RT, terminateurs de chaîne, ils contournent la résistance associée au mutant K65R. Notre objectif est donc de les pousser plus loin dans le « pipe-line » du développement de médicaments antiviraux.The Human Immunodeficiency Virus type 1 and type 2 (HIV-1 and HIV-2) and Hepatitis B (HBV) constitue a special interest in public health. Indeed, it is estimated that more than 33 million people infected with HIV worldwide and 360 million with HBV. Reverse transcriptase (RT) is an enzyme required for their replication and is therefore a key target for antiviral drugs. Among the NRTI marketed, nucleotide analogues like acyclic phosphonates, such as adefovir (Hepsera ®, Gilead) and Tenofovir (VIREAD ®, Gilead) as a prodrug form, have revolutionized the treatment against HBV and HIV. With the emmergence of resistant virus, there is a need to develop new antiviral compounds that are targetting especially these to optimize antiviral combination therapies. For this purpose, we designed analogues thiophosphonates derivatives Adefovir (PMEA) and tenofovir (PMPA), that are non-toxic in cells and active against HIV-1, HBV and HIV-2 infected cell cultures. These compounds, named Adethiovir Tenothiovir, were synthesized according to an original method and were the subject of a patent. We synthesized the corresponding diphosphates forms: incorporated by RT, chain terminators, they bypass the resistance associated with the K65R mutant. Our goal is to push them further in the "pipeline" development of antiviral drugs
Modifications expérimentales de la morphogenèse du système racinaire de jeunes semis d'hévéa (Hevea brasiliensis)
National audienc
Réaction géotropique des différents types de racines chez l'hévéa (Hevea brasiliensis)
National audienc
Synchronismes entre processus de developpement aerien et racinaire chez de jeunes semis d'hevea
National audienc
2,4-Substituted bispidines as rigid hosts for versatile applications: from Îş-opioid receptor to metal coordination
International audiencea Bispidones (3,7-diazabicyclo[3.3.1]nonan-9-one) are bicyclic analogues of the natural antiarrythmic agent, spartein. They can straightforwardly be obtained from two successive Mannich reactions. Reduction of the ketone gives the corresponding bispidol. Substituted bispidones and bispidols offer a large playground by varying the substituents, the configuration of the carbon atoms in position 2 and 4 as well as the conformation of the bicycle. While chair-boat conformers display a strong affinity for Îş-opioid receptors, chair-chair bispidines provide adaptable coordination spheres for transition metal and rare-earth ions. Because of their very rich coordination chemistry, substituted bispidines have emerged in various applications of coordination chemistry, such as catalysis, magnetism and medical imaging
- …